
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MAGE-A1 CRISPR/Cas9 KO Plasmid (h) | sc-401056 | 20 µg | $397.00 |
MAGEA1 encodes MAGE-A1, a cancer-testis antigen normally restricted to germ cells but frequently re-expressed in diverse malignancies, where it can contribute to tumor-associated transcriptional and proteostasis programs. MAGE-A1 belongs to the type I MAGE family and is implicated in protein–protein interactions that modulate ubiquitin-dependent pathways, including regulation of E3 ligase activity and turnover of signaling components. Aberrant MAGEA1 expression is associated with altered cell-cycle control, stress responses, and immune-recognition phenotypes that shape tumor biology. As a lineage-restricted antigen, MAGE-A1 is also widely used as a molecular marker in studies of tumor immunogenicity and epigenetic derepression.
MAGE-A1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MAGEA1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MAGEA1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MAGEA1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish MAGE-A1 protein expression.
This CRISPR knockout system enables efficient generation of MAGEA1-deficient cell models for investigation of MAGE-A1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.